Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
Total Valuation
Bicara Therapeutics Inc. has a market cap or net worth of $1.34B. The enterprise value is $1.08B.
Market Cap$1.34B
Enterprise Value$1.08B
Share Statistics
Bicara Therapeutics Inc. has 65,467,186 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding65,467,186
Owned by Insiders22.54%
Owned by Institutions49.69%
Financial Efficiency
Bicara Therapeutics Inc.’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -38.54%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-38.54%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-2.51M
Employee Count55
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bicara Therapeutics Inc. is ―. Bicara Therapeutics Inc.’s PEG ratio is -0.07.
PE Ratio―
PS Ratio0.00
PB Ratio2.29
Price to Fair Value2.29
Price to FCF-8.59
Price to Operating Cash Flow-11.08
PEG Ratio-0.07
Income Statement
In the last 12 months, Bicara Therapeutics Inc. had revenue of 0.00 and earned -137.95M in profits. Earnings per share was -2.52.
Revenue0.00
Gross Profit0.00
Operating Income-155.60M
Pretax Income-137.73M
Net Income-137.95M
EBITDA-155.60M
Earnings Per Share (EPS)-2.52
Cash Flow
In the last 12 months, operating cash flow was -106.83M and capital expenditures -280.00K, giving a free cash flow of -107.11M billion.
Operating Cash Flow-106.83M
Free Cash Flow-107.11M
Free Cash Flow per Share-1.64
Dividends & Yields
Bicara Therapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.38
52-Week Price Change73.29%
50-Day Moving Average17.34
200-Day Moving Average14.86
Relative Strength Index (RSI)66.89
Average Volume (3m)643.40K
Important Dates
Bicara Therapeutics Inc. upcoming earnings date is May 19, 2026, Before Open (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Bicara Therapeutics Inc. as a current ratio of 14.58, with Debt / Equity ratio of 0.43%
Current Ratio14.58
Quick Ratio14.58
Debt to Market Cap<0.01
Net Debt to EBITDA0.61
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bicara Therapeutics Inc. has paid -217.00K in taxes.
Income Tax-217.00K
Effective Tax Rate<0.01
Enterprise Valuation
Bicara Therapeutics Inc. EV to EBITDA ratio is -5.30, with an EV/FCF ratio of -7.70.
EV to Sales0.00
EV to EBITDA-5.30
EV to Free Cash Flow-7.70
EV to Operating Cash Flow-7.72
Balance Sheet
Bicara Therapeutics Inc. has $414.80M in cash and marketable securities with $1.71M in debt, giving a net cash position of $413.09M billion.
Cash & Marketable Securities$414.80M
Total Debt$1.71M
Net Cash$413.09M
Net Cash Per Share$6.31
Tangible Book Value Per Share$7.34
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bicara Therapeutics Inc. is $29.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$29.33
Price Target Upside43.07% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast―
EPS Growth Forecast-103.95%